- August 16, 2022
- Posted by: James Gansman
- Category: News
Sale of the Assets – Genocea Biosciences, Inc.
Genocea Biosciences, Inc. (“Genocea”) is a biopharmaceutical company dedicated to discovering and developing novel cancer immunotherapies using their proprietary ATLAS platform. Rock Creek Advisors, LLC has been engaged by Genocea to act on their behalf in seeking an interested party to purchase all the Company’s assets. Please note, this will be an expedited sale process.
Upon receipt of an executed confidentiality agreement in form and substance similar to the linked, and upon further receipt of an Indication of Interest demonstrating that you have a bona fide interest in providing a proposal to Genocea to purchase all the Company’s assets, Rock Creek will provide access information for Genocea’s confidential electronic data room.
Rock Creek will provide any interested party such due diligence access or information as Rock Creek determines to be reasonably requested and appropriate under the circumstances.
Rock Creek and the Genocea’s management team are available to discuss this opportunity at your convenience.
Genocea has entered into an agreement to sell its intellectual property and related assets to Harpy Holdings, LLC for the sum of $2,000,000. The sale is subject to higher and better offers. If you wish to submit a counteroffer, the offer must be in an amount of at least $2,150,000, and the offer must be received by Genocea by 12:00 Noon on September 16, 2022. If there are competing offers, an auction will be held on September 21, 2022 at 2:00 p.m. at the United States Bankruptcy Court in Boston, Massachusetts. Additional details are available in the Bidding Procedures Order which is attached hereto.
If there is another person at your firm who would be more appropriate to review this matter, please let us know and/or forward this information accordingly. Also, if your firm is not interested in pursuing this opportunity, your response and indication is much appreciated so that we do not follow up further.